Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2030

Conditions

ARBBVMDAutosomal-Dominant BestrophinopathyBest Vitelliform Macular Dystrophy

Interventions

GENETIC

OPGx-BEST1

Experimental Genetic Therapy

Trial Locations (1)

RECRUITING

Retina Foundation of the Southwest, Dallas